Pearl Steinzor

A randomized trial finds that default mailed outreach outperforms active choice strategies for initiating colorectal cancer screening in young adults.

Experts highlight advances in therapies, research on skin of color, and the impact of social determinants of health at the Society for Pediatric Dermatology's milestone annual meeting.

As rates of childhood obesity rise, clinicians call for increased data collection to support insurance coverage and safe use of glucagon-like peptide 1 (GLP-1) medications in children under 12 years.

In a large fecal immunochemical test-based screening program, high adenoma detection rates lowered interval colorectal cancer (CRC) incidence and mortality, but not CRC-specific survival.

Proper placement, device understanding, and ongoing support are key to helping children and adolescents with diabetes benefit from continuous glucose monitors (CGMs), explained Marry Vuong, PharmD, BCPPS, of Perfecting Peds.

A New Zealand study finds patients are open to remote and general practitioner-led care when it is tailored to their needs.

In an extension trial, apremilast showed sustained clinical benefit and a consistent safety profile in children and adolescents with moderate to severe plaque psoriasis.

The study aims to build an accurate, interpretable model for stage III colorectal cancer prognosis.

Elevated levels of per- and polyfluoroalkyl substances (PFAS), also known as “forever chemicals,” may be associated with metabolic disruptions potentially leading to type 2 diabetes.

At the Society for Pediatric Dermatology Annual Meeting, Sarah Coates, MD, FAAD, highlights how social drivers shape pediatric skin health and how clinicians can respond.

Two posters presented at the Society for Pediatric Dermatology's Annual Meeting explore the psychological toll and potential nutritional approaches for managing vitiligo in children and adolescents.

With obesity rates rising sharply, the American Academy of Pediatrics calls for multimodal strategies to address the crisis in youth.

A poster at the Society for Pediatric Dermatology Annual Meeting presented an integrated safety analysis showing rare or no serious adverse events linked to topical Janus kinase inhibitor use in children with atopic dermatitis (AD).

Culturally informed, patient-centered strategies are needed to address acne and hyperpigmentation in patients with skin of color.

New data highlight efficacy, safety, and time off treatment with as-needed ruxolitinib cream in pediatric atopic dermatitis.

The FDA cited trial design concerns and lack of substantial evidence in denying approval for Replimune’s biologics license application in advanced melanoma.

Mental health, care of acute and chronic conditions, primary care access and prevention, and maternal and perinatal health were identified as key focus areas among a majority of states.

No increased risk of thrombotic events identified despite rise in erythrocytosis among sodium-glucose cotransporter 2 inhibitor (SGLT2i) users with type 2 diabetes, study finds.

The Society for Pediatric Dermatology’s 50th Annual Meeting will highlight advances in pediatric skin, hair, and nail care, with expert-led sessions on cutting-edge research and therapies.

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

New research identifies diabetes as an independent predictor of major adverse cardiovascular events in patients with both psoriasis and coronary artery disease.

Patients and providers find the Colon Age tool acceptable and useful for individualizing colorectal cancer risk and encouraging earlier screening.

Adam Colborn, JD, associate vice president of congressional affairs at AMCP, shares insights on the impact of the Most Favored Nation drug pricing order when it comes to access, affordability, and innovations in US health care.

Survival models using electronic health record data show promise in predicting progression to proliferative diabetic retinopathy in patients with type 2 diabetes.

A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals with diverse skin tones.

New insights highlight clinician support for shared survivorship care and identify key factors for effective implementation.

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council guidelines.

Metformin use may enhance progression-free survival (PFS) in patients receiving first-line systemic therapy for patients with metastatic colorectal cancer.

Nicolas Ferreyros, managing director, Community Oncology Alliance, discusses key components of health equity and social determinants of health that need to be addressed in cancer care.

This new study identifies key contributors to mental health decline in individuals with atopic dermatitis, highlighting the need for integrated care.